THE WHAT? Skin + Me has raised more than €11 million in a Series B funding round. The round was led by Octopus Ventures, according to a report published by EU-Startups.
THE DETAILS Launched in 2020, the subscription-based dermatology brand offers custom-made treatments containing prescription-only actives.
“Octopus Ventures takes pride in backing companies that incite positive and actionable change,” Will Gibbs, Partner, Health, Octopus Ventures, reveals. “Increased awareness in prescription ingredients and a growing trend towards personalisation has transformed the skin care market. Skin + Me lead the charge with its accelerated growth reflecting a step change that’s seen hyper-educated consumers shun off-the-shelf products in favour of highly efficacious solutions. Across Series A and Series B funding, Octopus Ventures has invested a total of £13m to develop Skin + Me — deepening the relationship, and demonstrating their faith in the brand’s market-leading personalisation strategy.”
THE WHY? Horatio Cary, Co-Founder and CEO of Skin + Me, told EU Start-ups, “The global skin care industry is worth £140 billion and more than 50 percent of consumers are dissatisfied because they want a product that works. We built Skin + Me to make medical skincare, proven to be far more effective than any cosmetic products through decades of clinical studies, accessible to everyone. Loyalty and customer love for our products followed because they deliver results.
“We’ve seen consumer awareness for prescription-only ingredients such as tretinoin grow exponentially. We expect the £140 billion global skin care spend to shift quickly towards prescription-strength ingredients and Skin + Me is ideally placed as the market leader in the UK to take advantage of this trend.”